Announced details
Treatment of IgA nephropathy in adults
OPDC, Otsuka Pharmaceutical's US subsidiary, is submitting a supplemental biologics license application (sBLA) to the FDA.
US drug regulatory authority. Other details: not disclosed.
Otsuka Pharmaceutical Development & Commercialization, Inc.: Princeton, New Jersey, US
There is currently no change to the company's consolidated earnings forecast for the fiscal year ending December 2026. The company considers this an important development toward enhancing corporate value over the medium to long term.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | VOYXACT® (sibeprenlimab) |
| Counterparty | U.S. Food and Drug Administration (FDA) |
| Counterparty overview | US drug regulatory authority. Other details: not disclosed. |
| Relationship with the Company | OPDC, Otsuka Pharmaceutical's US subsidiary, is submitting a supplemental biologics license application (sBLA) to the FDA. |
| Applicable area | Treatment of IgA nephropathy in adults |
| Location | Otsuka Pharmaceutical Development & Commercialization, Inc.: Princeton, New Jersey, US |
| Impact on Business Performance | There is currently no change to the company's consolidated earnings forecast for the fiscal year ending December 2026. The company considers this an important development toward enhancing corporate value over the medium to long term. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This is part of the application process to obtain Traditional Approval for VOYXACT, which the company positions as one of the products that will drive future growth.